Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 15, 2024

Via Benzinga

Why Are Stocks Up Today? ↗

April 15, 2024

Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday!

Via InvestorPlace

Crude Oil Down 1%; Charles Schwab Sales Top Estimates ↗

April 15, 2024

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P...

Via Benzinga

Topics Stocks

DJT Stock Alert: Trump Media Plunges on Share Sale Panic ↗

April 15, 2024

Trump Media & Technology stock is falling hard on Monday as investors react to a filing for a secondary offering of DJT shares.

Via InvestorPlace

Topics Government

Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today? ↗

April 15, 2024

Marinus Pharmaceuticals stock is falling on Monday with heavy trading of MRNS shares after posting an update on a Phase 3 trial.

Via InvestorPlace

Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights ↗

March 26, 2024

Via Benzinga

Leverage Shares -3x Short Moderna (MRNA) ETP Securities: Q4 Earnings Insights ↗

March 05, 2024

Via Benzinga

Marinus Pharma's Earnings Outlook ↗

March 04, 2024

Via Benzinga

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

April 15, 2024

From Schall Law

Via GlobeNewswire

Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday? ↗

April 15, 2024

Marinus Pharmaceuticals provides updates on Phase 3 RAISE trial for refractory status epilepticus treatment with IV ganaxolone. With enrollment completion expected, topline results are anticipated by...

Via Benzinga

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings ↗

April 15, 2024

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also...

Via Benzinga

Topics Stocks

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

April 15, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Via Benzinga

Topics Stocks

Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) is a Stock Spotlight on 1/5

January 05, 2024

Via Investor Brand Network

Analyst Expectations for Marinus Pharma's Future ↗

December 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 15, 2024

Via Benzinga

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results

April 15, 2024

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

April 05, 2024

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

March 27, 2024

From Marinus Pharmaceuticals

Via Business Wire

MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023 ↗

March 05, 2024

MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 05, 2024

Via Benzinga

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 05, 2024

From Marinus Pharmaceuticals

Via Business Wire

Earnings Scheduled For March 5, 2024 ↗

March 05, 2024

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.

Via Benzinga

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

February 21, 2024

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024

February 20, 2024

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 16, 2024

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

January 04, 2024

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update

January 04, 2024

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 07, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study

November 20, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference

November 14, 2023

From Marinus Pharmaceuticals

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.